Insurance Coverage and Cash-Pay Models

Coverage of a drug is a structure rather than a yes or no: formulary tier, prior authorisation, step therapy through a cheaper agent first, quantity limits, and eligibility criteria such as a body mass index threshold. Paying cash removes every gate and the negotiated net price that rebates produce. Manufacturer direct-to-patient channels sit between, publishing a self-pay price below list but above what a covered patient faces.

Obesity pharmacotherapy shows the machinery clearly. In the United States, Medicare's outpatient drug benefit has excluded agents used for weight loss since its creation, so coverage arrived indirectly: after a cardiovascular outcomes trial supported a risk-reduction indication, plans were told they could cover the product for that indication rather than for obesity itself. Branded list prices have run above a thousand dollars a month while manufacturers' self-pay vial channels were priced in the hundreds, and several employer and state plans dropped coverage on cost grounds.

Price determines persistence, and persistence determines outcome. These are chronic therapies whose effect regresses after discontinuation, so the number that matters is sustained annual cost. It also explains why cost and product-integrity questions arrive together: a coverage denial is the commonest point at which a patient starts considering compounded or unofficial supply, so pricing shapes safety exposure.

The arithmetic is misread in two ways. Comparing a cash price with an insured copay sets a gross price against a cost-shared slice of a rebated net price, so the multiple overstates the real difference. And an advertised monthly figure is usually the drug alone: the clinic or telehealth membership, the laboratory panel and the move to a higher-priced strength all sit outside it, which is why the first month rarely predicts the twelfth.